Table 1 Distribution and prognostic impact of CDX2 expression, staging parameters as well as CRC subtypes, tumour budding and WHO grade in the overall cohort.
Overall, n (%) | Median overall survival (SE) | P value | Mean disease-specific survival (SE) | P value | Mean disease-free survival (SE) | P value | |
|---|---|---|---|---|---|---|---|
Age | <0.001 | 0.01 | 0.68 | ||||
Below median | 492 (49%) | 146.1 (5.4) | 163.9 (4.9) | 149.5 (5.1) | |||
Above median | 511 (51%) | 101.1 (4.8) | 133.3 (4.7) | 135.9 (4.6) | |||
Sex | 0.39 | 0.79 | 0.71 | ||||
Male | 575 (57.3%) | 125.5 (5.1) | 157.6 (4.7) | 151.9 (4.8) | |||
Female | 428 (42.7%) | 122.1 (5.1) | 138.8 (4.9) | 133.1 (5.0) | |||
CDX2 subgroups | 0.017 | 0.006 | 0.005 | ||||
CDX2-low/absent | 102 (10.2%) | 100.38 (10.3) | 121.9 (10.7) | 114.9 (10.7) | |||
CDX2-high | 901 (89.8%) | 131.28 (3.8) | 158.7 (3.8) | 153.1 (3.8) | |||
pT | <0.001 | <0.001 | <0.001 | ||||
1 | 78 (7.8%) | 139.1 (8.4) | 172.4 (4.8) | 165.2 (6.2) | |||
2 | 182 (18.1%) | 140.5 (6.6) | 164.6 (5.9) | 161.0 (6.0) | |||
3 | 554 (55.3%) | 125.8 (5.3) | 156.5 (5.0) | 148.7 (5.1) | |||
4 | 189 (18.8%) | 87.8 (7.3) | 96.4 (7.6) | 90.6 (3.7) | |||
pN | <0.001 | <0.001 | <0.001 | ||||
0 | 552 (55%) | 141.0 (4.5) | 173.9 (4.1) | 174.3 (4.0) | |||
1 | 284 (28.3%) | 112.2 (5.6) | 124.9 (5.6) | 115.2 (5.8) | |||
2 | 167(16.7%) | 83.4 (8.7) | 91.9 (8.9) | 67.4 (8.6) | |||
pM | <0.001 | <0.001 | <0.001 | ||||
0 | 851 (84.9%) | 142.4 (4.3) | 174.0 (3.8) | 169.1 (3.8) | |||
1 | 152 (15.1%) | 48.7 (5.0) | 53.2 (5.4) | 41.5 (5.18) | |||
UICC stage | <0.001 | <0.001 | <0.001 | ||||
1 | 207 (20.6%) | 147.4 (5.9) | 178.9 (4.5) | 175.9 (4.7) | |||
2 | 326 (32.5%) | 133.6 (6.0) | 164.0 (6.5) | 167.8 (5.5) | |||
3 | 318 (31.8%) | 130.2 (7.5) | 153.8 (6.5) | 136.9 (6.6) | |||
4 | 152 (15.1%) | 48.3 (5.0) | 52.8 (3.6) | 41.5 (5.1) | |||
Tumour type (WHO) | <0.001 | <0.001 | <0.001 | ||||
Adenocarcinoma NOS | 630 (62.8%) | 137.2 (3.9) | 164.7 (4.4) | 159.7 (4.4) | |||
Mucinous adenocarcinoma | 83 (8.3%) | 100.4 (9.0) | 118.2 (9.4) | 109.2 (9.7) | |||
Signet-ring cell carcinoma | 9 (0.9%) | 65.5 (28.3) | 65.4 (28.3) | 40.2 (23.8) | |||
Medullary adenocarcinoma | 32 (3.2%) | 147.9 (13.5) | 188.0 (6.5) | 181.5 (8.9) | |||
Micropapillary adenocarcinoma | 122 (12.2%) | 79.1 (9.0) | 88.4 (9.7) | 76.6 (9.5) | |||
Serrated adenocarcinoma | 87 (8.6%) | 119.6 (10.4) | 141.7 (10.0) | 133.7 (5.5) | |||
Adenoma-like adenocarcinoma | 33 (3.3%) | 132.0 (12.3) | 170.6 (7.9) | 176.8 (5.5) | |||
MANEC/NEC | 7 (0.7%) | 18.0 (8.1) | 18.0 (8.1) | 17.5 (9.3) | |||
WHO grade | <0.001 | <0.001 | <0.001 | ||||
Low grade | 685 (68%) | 135.3 (4.3) | 162.7 (4.0) | 155.8 (4.0) | |||
High grade | 318 (32%) | 104.2 (6.3) | 125.7 (6.4) | 120.6 (6.6) | |||
Tumour budding | <0.001 | <0.001 | <0.001 | ||||
Bd1 | 545 (54%) | 160.9 (4.4) | 192.3 (3.4) | 190.6 (3.3) | |||
Bd2 | 261 (26%) | 108.6 (8.0) | 131.1 (7.2) | 113.8 (7.2) | |||
Bd3 | 197 (20%) | 48.5 (4.6) | 56.2 (5.4) | 48.5 (5.3) | |||
Resection margin | <0.001 | <0.001 | <0.001 | ||||
R0 | 932 (92.9%) | 135.8 (4.1) | 166.8 (3.7) | 160.2 (3.7) | |||
R1 | 41 (4.1%) | 50.9 (10.5) | 53.6 (11.0) | 36.9 (9.5) | |||
R2 | 30 (3%) | 26.1 (5.4) | 26 (5.4) | 21.5 (3.7) | |||
Lymphatic invasion | <0.001 | <0.001 | <0.001 | ||||
Not present | 495 (49.3%) | 141.2 (4.8) | 174.9 (4.3) | 175.8 (4.2) | |||
Present | 508 (50.7%) | 111.1 (5.7) | 129.9 (5.3) | 116.2 (5.3) | |||
Venous invasion | <0.001 | <0.001 | <0.001 | ||||
Not present | 870 (86.8%) | 136.2 (4.2) | 166.8 (3.7) | 162.8 (3.8) | |||
Present | 133 (13.2%) | 74.9 (9.1) | 79.06 (9.6) | 63.3 (8.6) | |||
Perineural invasion | <0.001 | <0.001 | <0.001 | ||||
Not present | 936 (93.3%) | 132.6 (4.1) | 162.1 (3.7) | 158.0 (3.7) | |||
Present | 67 (6.7%) | 50.4 (6.1) | 50.4 (6.1) | 35.1 (5.4) | |||
Microsatellite status | 0.01 | 0.01 | 0.01 | ||||
Microsatellite stable | 849 (84.6%) | 125.5 (4.2) | 151.68 (4.0) | 145.3 (4.0) | |||
Microsatellite instable | 154 (15.4%) | 137.0 (8.0) | 165.7 (7.2) | 162.8 (7.2) | |||
Tumour localisation | 0.18 | 0.38 | 0.33 | ||||
Caecum | 147 (14.7%) | 109.2 (6.9) | 130.0 (6.2) | 128.9 (6.8) | |||
Ascending colon | 256 (25.5%) | 120.5 (6.3) | 143.2 (6.8) | 132.9 (6.4) | |||
Transverse colon | 82 (8.2%) | 89.0 (8.6) | 110.1 (9.1) | 112.1 (9.4) | |||
Descending colon | 92 (9.2%) | 128.1 (11.7) | 143.3 (11.9) | 143.1 (11.8) | |||
Sigmoid colon | 318 (31.7%) | 136.6 (6.7) | 162.4 (6.2) | 156.2 (6.3) | |||
Rectum | 108 (10.8%) | 103.9 (8.6) | 119.9 (9.2) | 110.2 (9.4) |
